ID | 119253 |
Author |
Kitamura, Naoya
Kochi University
Sento, Shinya
Kochi University
Yoshizawa, Yasumasa
Kochi University
Sasabe, Eri
Kochi University
Kudo, Yasusei
Tokushima University
Tokushima University Educator and Researcher Directory
KAKEN Search Researchers
Yamamoto, Tetsuya
Kochi University
|
Keywords | head and neck squamous cell carcinoma
molecular targeted therapy
cetuximab
immune checkpoint inhibitor
multi-oncogene panel test
photoimmunotherapy
|
Content Type |
Journal Article
|
Description | In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.
|
Journal Title |
International Journal of Molecular Sciences
|
ISSN | 14220067
|
Publisher | MDPI
|
Volume | 22
|
Issue | 1
|
Start Page | 240
|
Published Date | 2020-12-29
|
Rights | This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
|
EDB ID | |
DOI (Published Version) | |
URL ( Publisher's Version ) | |
FullText File | |
language |
eng
|
TextVersion |
Publisher
|
departments |
Oral Sciences
|